Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorCevik, Muge
dc.contributor.authorOrkin, Chloe
dc.contributor.authorSax, Paul E
dc.date.accessioned2020-08-03T11:30:08Z
dc.date.available2020-08-03T11:30:08Z
dc.date.issued2020-06
dc.identifier.citationCevik , M , Orkin , C & Sax , P E 2020 , ' Emergent resistance to dolutegravir among INSTI-naïve patients on first-line or second-line antiretroviral therapy : a review of published cases ' , Open Forum Infectious Diseases , vol. 7 , no. 6 , ofaa202 . https://doi.org/10.1093/ofid/ofaa202en
dc.identifier.issn2328-8957
dc.identifier.otherPURE: 269436080
dc.identifier.otherPURE UUID: 68350e0d-966b-4654-bcd2-84b8b3632e1d
dc.identifier.otherPubMed: 32587877
dc.identifier.otherPubMedCentral: PMC7304932
dc.identifier.otherWOS: 000565181000035
dc.identifier.otherScopus: 85092064339
dc.identifier.urihttp://hdl.handle.net/10023/20395
dc.description.abstractNone of the licensing studies of dolutegravir (DTG) reported any treatment-emergent resistance among DTG-treated individuals, though virological failure in treatment-naïve and treatment-experienced, integrase strand transfer inhibitor (INSTI)-naïve individuals has been reported in clinical practice. While the spectrum of dolutegravir-selected mutations and their effects on clinical outcome have been described, the clinical characteristics of these rare but important virological failure cases are often overlooked. In this perspective piece, we focus on key clinical aspects of emergent resistance to DTG among treatment-naïve and treatment-experienced INSTI-naïve patients, with an aim to inform clinical decision-making. Poor adherence and HIV disease factors contribute to emergent drug resistance, even in regimens with high resistance barriers. Patients with severe immunosuppression or poor adherence are under-represented in licensing studies, and these patients may be at higher risk of treatment failure with DTG resistance, which requires close clinical and laboratory follow-up.
dc.format.extent4
dc.language.isoeng
dc.relation.ispartofOpen Forum Infectious Diseasesen
dc.rightsCopyright © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.comen
dc.subjectDolutegraviren
dc.subjectHIVen
dc.subjectTreatment failureen
dc.subjectTreatment-naïveen
dc.subjectResistanceen
dc.subjectQR180 Immunologyen
dc.subjectQR355 Virologyen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subject.lccQR180en
dc.subject.lccQR355en
dc.subject.lccRMen
dc.titleEmergent resistance to dolutegravir among INSTI-naïve patients on first-line or second-line antiretroviral therapy : a review of published casesen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. Infection and Global Health Divisionen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doihttps://doi.org/10.1093/ofid/ofaa202
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record